CHU Pitié Salpetriere
Paris, 75013, France
NCT Number: NCT01530685
The purpose of this study is to examine the effects of supplementation Glycabiane, a dietary supplement, on glycemic control of overweight prediabetic subjects.
Looking for future studies?
Notify Me25 year–65 year
All sexes
Interventional
Not applicable
Paris, 75013, France
Cinnamon's effects on blood glucose have been the subject of many clinical and animal studies; however, the issue of cinnamon intake's effect on fasting blood glucose (FBG) in people with prediabetes still remains unclear.
The main purpose of this study is to examine the effects of supplementation with Glycabiane, a dietary supplement rich in cinnamon extract, on fast blood glucose of overweight prediabetic subjects in a randomized, placebo-controlled, clinical trial.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
2 gelule per day for 4 months
Other names: Dietary supplement
2 gelules per day for 4 months
Time frame: 4 months
Fast blood glucose will be measured before and after 4 months of supplementation and after 2 months of wash-out
PiLeJe
Industry
Effect of Glycabiane, a Dietary Supplement, on Glycemic Control of Prediabetic Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05056376
Behavior, Body Weight
Baltimore, Maryland, United States
View Trial DetailsNCT05730231
Antioxidative Stress, Behavior
Izola, Slovenia
View Trial DetailsNCT05329610
Body Weight, Diabetes Mellitus
Nottingham, Nottinghamshire, United Kingdom
View Trial DetailsNCT01428791
Behavior, Behavioral Symptoms
Chicago, Illinois, United States
View Trial Details